Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival

详细信息查看全文

作者：H. Frydenberg ; I. Thune ; T. Lofterød…
关键词：CRP ; Inflammation markers ; Breast cancer
刊名：Breast Cancer Research and Treatment
出版年：2016
出版时间：January 2016
年：2016
卷：155
期：2
页码：345-354
全文大小：680 KB
参考文献：1.Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8):1093–1102. doi:10.1038/onc.2009.416 CrossRef PubMed
2.Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi:10.1038/nature07205 CrossRef PubMed
3.Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013 CrossRef PubMed
4.Allin KH, Nordestgaard BG, Flyger H, Bojesen SE (2011) Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 13(3):R55. doi:10.1186/bcr2891 PubMedCentral CrossRef PubMed
5.Chan DS, Bandera EV, Greenwood DC, Norat T (2015) Circulating C-reactive protein and breast cancer risk—systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomark Prev. doi:10.1158/1055-9965.epi-15-0324
6.Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA J Am Med Assoc 282(22):2131–2135CrossRef
7.Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY (2015) Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J Natl Cancer Inst. doi:10.1093/jnci/djv169
8.Macinnis RJ, English DR, Gertig DM, Hopper JL, Giles GG (2004) Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev 13(12):2117–2125
9.Suzuki S, Kojima M, Tokudome S, Mori M, Sakauchi F, Wakai K, Fujino Y, Lin Y, Kikuchi S, Tamakoshi K, Tamakoshi A (2013) Obesity/weight gain and breast cancer risk: findings from the Japan collaborative cohort study for the evaluation of cancer risk. J Epidemiol Japan Epidemiol Assoc 23(2):139–145CrossRef
10.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. doi:10.1016/s0140-6736(08)60269-x CrossRef PubMed
11.Harvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229:45–52. doi:10.1111/j.1749-6632.2011.06096.x CrossRef PubMed
12.Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G, Rahnenfuhrer J, Hengstler JG, Schmidt M (2014) Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS ONE 9(10):e111306. doi:10.1371/journal.pone.0111306 PubMedCentral CrossRef PubMed
13.Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27(21):3437–3444. doi:10.1200/jco.2008.18.9068 PubMedCentral CrossRef PubMed
14.Nyrnes A, Njolstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Skjelbakken T, Jorgensen L, Lochen ML (2012) Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromso study. Gender Med 9(6):536–547.e532. doi:10.1016/j.genm.2012.09.001
15.Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709):132–140. doi:10.1016/s0140-6736(09)61717-7 CrossRef PubMed
16.Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, Taib NA (2015) Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113(1):150–158. doi:10.1038/bjc.2015.183 PubMedCentral CrossRef PubMed
17.Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, Somali I, Demir L, Bayoglu IV, Yildiz Y, Akyol M, Koyuncu B, Coban E, Ulger E, Unay FC, Tarhan MO (2015) Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol 20(1):70–81. doi:10.1007/s10147-014-0672-8 CrossRef PubMed
18.Eggen AE, Mathiesen EB, Wilsgaard T, Jacobsen BK, Njolstad I (2013) The sixth survey of the Tromso Study (Tromso 6) in 2007–2008: collaborative research in the interface between clinical medicine and epidemiology: study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey. Scand J Public Health 41(1):65–80. doi:10.1177/1403494812469851 CrossRef PubMed
19.Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I (2012) Cohort profile: the Tromso Study. Int J Epidemiol 41(4):961–967. doi:10.1093/ije/dyr049 PubMedCentral CrossRef PubMed
20.Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M (2015) Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis. doi:10.1093/carcin/bgv096 PubMed
21.Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20(1):15–26. doi:10.1007/s10552-008-9212-z CrossRef PubMed
22.Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, Ridker PM (2007) C-reactive protein and risk of breast cancer. J Natl Cancer Inst 99(11):890–894. doi:10.1093/jnci/djk202 CrossRef PubMed
23.Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, Fagherazzi G, Clavel-Chapelon F, Mesrine S (2014) C-reactive protein and postmenopausal breast cancer risk: results from the E3 N cohort study. Cancer Causes Control 25(4):533–539. doi:10.1007/s10552-014-0355-9 CrossRef PubMed
24.Wang G, Li N, Chang S, Bassig BA, Guo L, Ren J, Su K, Li F, Chen S, Wu S, Zou Y, Dai M, Zheng T, He J (2015) A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomark Prev 24(2):459–465. doi:10.1158/1055-9965.epi-14-1112 CrossRef
25.Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT (2013) Distribution and determinants of C-reactive protein in the older adult population: European Prospective Investigation into Cancer-Norfolk study. Eur J Clin Invest 43(9):899–911. doi:10.1111/eci.12116 CrossRef PubMed
26.Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA, Fini M, Mercuro G, Rosano GM (2003) Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 107(25):3165–3169. doi:10.1161/01.cir.0000074208.02226.5e CrossRef PubMed
27.Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A (2007) Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 167(17):1837–1844. doi:10.1001/archinte.167.17.1837 CrossRef PubMed
28.Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, Zhang W, Sun Q, Zhao Y (2011) Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Mark 26(4):209–215. doi:10.5301/jbm.2011.8872
29.Tibau A, Ennis M, Goodwin PJ (2013) Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Res Treat 141(3):485–493. doi:10.1007/s10549-013-2694-8 CrossRef PubMed
30.O’Hanlon DM, Lynch J, Cormican M, Given HF (2002) The acute phase response in breast carcinoma. Anticancer Res 22(2b):1289–1293PubMed
31.Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Moller B (2009) Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer (Oxford, England: 1990) 45 (7):1218–1231. doi:10.1016/j.ejca.2008.10.037
32.Imayama I, Alfano CM, Neuhouser ML, George SM, Wilder Smith A, Baumgartner RN, Baumgartner KB, Bernstein L, Wang CY, Duggan C, Ballard-Barbash R, McTiernan A (2013) Weight, inflammation, cancer-related symptoms and health related quality of life among breast cancer survivors. Breast Cancer Res Treat 140(1):159–176. doi:10.1007/s10549-013-2594-y PubMedCentral CrossRef PubMed
作者单位：H. Frydenberg (1)
I. Thune (1) (2)
T. Lofterød (1)
E. S. Mortensen (3)
A. E. Eggen (4)
T. Risberg (5)
E. A. Wist (1)
V. G. Flote (1)
A-S Furberg (4) (6)
T. Wilsgaard (4)
L. A. Akslen (7)
A. McTiernan (8)

1. Department of Oncology, The Cancer Centre, Ullevål, Oslo University Hospital HF, 0424, Oslo, Norway
2. Institute of Clinical Medicine, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway
3. Molecular Pathology Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway
4. Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway
5. Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
6. Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway
7. Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway
8. Fred Hutchinson Cancer Research Center, Seattle, WA, USA
刊物类别：Medicine
刊物主题：Medicine & Public Health
Oncology
出版者：Springer Netherlands
ISSN：1573-7217

文摘

Inflammation may initiate and promote breast cancer development, and be associated with elevated circulating levels of inflammation markers. A total of eight 130 initially healthy women, participated in the population-based Tromsø study (1994–2008). Pre-diagnostic high-sensitivity C-reactive protein (hs-CRP) was assessed. During 14.6 years of follow-up, a total of 192 women developed invasive breast cancer. These cases were followed for additional 7.2 years. Detailed medical records were obtained. We observed an overall positive dose–response relationship between pre-diagnostic hs-CRP and breast cancer risk (hazard ratio (HR) = 1.06, 95 % CI 1.01–1.11). Postmenopausal women with above median levels of hs-CRP (>1.2 mg/l) had a 1.42 (95 % CI 1.01–2.00) higher breast cancer risk compared to postmenopausal women with hs-CRP below median. Postmenopausal women, who were hormone replacement therapy non-users, and were in the middle tertile (0.8–1.9 mg/l), or highest tertile of hs-CRP (>1.9 mg/l), had a 2.31 (95 % CI 1.31–4.03) and 2.08 (95 % CI 1.16–3.76) higher breast cancer risk, respectively, compared with women in the lowest tertile. For each unit increase in pre-diagnostic hs-CRP levels (mg/l), we observed an 18 % increase in disease-free interval (95 % CI 0.70–0.97), and a 22 % reduction in overall mortality (95 % CI 0.62–0.98). Our study supports a positive association between pre-diagnostic hs-CRP and breast cancer risk. In contrast, increased pre-diagnostic hs-CRP was associated with improved overall mortality, but our findings are based on a small sample size, and should be interpreted with caution. Keywords CRP Inflammation markers Breast cancer